FIG 1.
Patient populations used for analysis. Safetya, all subjects who received at least 1 dose of study drug; PKb, all subjects who received at least 1 dose of study drug and had sufficient plasma concentration data to calculate the primary PK parameters; ECGc, all subjects who were randomly assigned, received at least 1 dose of study drug, and had at least 1 baseline (predose) ECG and 1 on-treatment (postdose) ECG within the same treatment period; PK/PDd, all subjects in the ECG population with time-matched plasma concentrations. ECG, electrocardiographic; PD, pharmacodynamic; PK, pharmacokinetic.